Provided by Tiger Trade Technology Pte. Ltd.

Cognition Therapeutics, Inc

1.04
-0.0200-1.89%
Post-market: 1.03-0.0100-0.96%19:57 EDT
Volume:336.51K
Turnover:355.19K
Market Cap:98.90M
PE:-5.37
High:1.07
Open:1.06
Low:1.04
Close:1.06
52wk High:2.05
52wk Low:0.5501
Shares:95.09M
Float Shares:85.42M
Volume Ratio:0.76
T/O Rate:0.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1936
EPS(LYR):-0.3228
ROE:-83.76%
ROA:-78.18%
PB:2.99
PE(LYR):-3.22

Loading ...

Amazon - Cognition and AWS Sign Multi-Year Strategic Collaboration Agreement

THOMSON REUTERS
·
Sep 15

Cognition Therapeutics CEO Lisa Ricciardi Presents at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 08

Soligenix Q2 Net Loss Narrows as R&D Expenses Fall

Reuters
·
Aug 07

Cognition Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Cognition Therapeutics reports Q2 EPS (4c), consensus (6c)

TIPRANKS
·
Aug 07

Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate

Benzinga Earnings
·
Aug 07

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

THOMSON REUTERS
·
Aug 07

Cognition Therapeutics Q2 Income from Operations USD -7.738 Million

THOMSON REUTERS
·
Aug 07

Cognition Therapeutics Inc Expected to Post a Loss of 6 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth?

Simply Wall St.
·
Jul 16

Cognition Therapeutics Posts Press Release on B. Riley Summit Fireside Chat to IR Website

Reuters
·
Jul 13

H.C. Wainwright Keeps Their Buy Rating on Cognition Therapeutics (CGTX)

TIPRANKS
·
Jun 25

Cognition Therapeutics gets FDA feedback on zervimesine study

TIPRANKS
·
Jun 24

Cognition Therapeutics Targets Mid-2027 Start for Phase 3 Zervimesine Trial in DLB Psychosis

Reuters
·
Jun 24

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (ct1812) in Dlb Psychosis Following Receipt of FDA Meeting Minutes

THOMSON REUTERS
·
Jun 24

Cognition Therapeutics - Registrational Program for Zervimesine in Dlb Psychosis to Begin Mid-2027

THOMSON REUTERS
·
Jun 24

Cognition Therapeutics - to Use Neuropsychiatric Inventory as Primary Endpoint in Pivotal Dlb Psychosis Trial

THOMSON REUTERS
·
Jun 24

H.C. Wainwright Reaffirms Their Buy Rating on Cognition Therapeutics (CGTX)

TIPRANKS
·
Jun 22

Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor

TIPRANKS
·
Jun 18

Cognition Therapeutics shareholders elect Aaron Fletcher, Lisa Ricciardi as Class II directors

Reuters
·
Jun 18